Uncategorized

Summit has less than a year of cash runway left as PD-1/VEGF verdict nears

Published

on

Summit’s star asset is the PD-1/VEGF bispecific ivonescimab, which this week produced promising survival data from a late-stage global trial in non-small cell lung cancer. The FDA review is ongoing with a decision expected by Nov. 14.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version